HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China
23 janv. 2023 03h00 HE
|
HUTCHMED (China) Limited
— HUTCHMED to receive US$400 million upfront on deal closing and up to US$730 million in potential future milestone payments, totaling up to US$1.13 billion, plus royalties on net sales — — Marketing...
HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China
18 janv. 2023 09h30 HE
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 18, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces, following negotiations with the...
HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China
03 janv. 2023 03h30 HE
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) today announces that it has completed...
HUTCHMED Initiates Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Colorectal Cancer
19 déc. 2022 05h00 HE
|
HUTCHMED (China) Limited
— Company plans to complete rolling submission to the U.S. in the first half of 2023, followed by filings in Europe and Japan — — NDA is supported by global Phase III FRESCO-2 study conducted...
HUTCHMED Announces Strategy to Focus on Late-Stage Pipeline Regulatory Approvals
14 nov. 2022 19h00 HE
|
HUTCHMED (China) Limited
Reprioritization accelerating path to profitability Evaluation of partnership opportunities for select late-stage assets HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Nov. 14, 2022...
HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China
13 nov. 2022 19h00 HE
|
HUTCHMED (China) Limited
— Results of dual primary endpoint study showed statistically significant and clinically meaningful benefit in progression-free survival, a primary endpoint — — Overall survival, the other primary...
HUTCHMED Initiates a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China
27 oct. 2022 07h30 HE
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase...
HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
10 oct. 2022 04h30 HE
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 10, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase...
HUTCHMED Highlights Phase III FRESCO-2 MRCT Data Summary of Fruquintinib in Refractory Metastatic Colorectal Cancer from the Upcoming ESMO 2022 Presentation
07 sept. 2022 18h30 HE
|
HUTCHMED (China) Limited
— Fruquintinib treatment reduced the risk of death by 34% in metastatic colorectal cancer (0.66 HR) — — Increased disease control with risk of disease progression or death reduced by 68% (0.32...
HUTCHMED Highlights Fruquintinib MRCT FRESCO-2 Data to be Presented at the Upcoming ESMO Congress 2022
23 août 2022 04h30 HE
|
HUTCHMED (China) Limited
— Trial met primary endpoint of overall survival and all secondary endpoints — — Selected as a late-breaker presentation — — Conference call and webcast to be held on Monday, September 12 at...